The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER+) breast cancer or advanced solid tumors.
 
Kevin Kalinsky
Stock and Other Ownership Interests - Array BioPharma (I); GRAIL (I); Pfizer (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; bioTheranostics; Cyclacel; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; immunomedics; Ipsen; Lilly; Merck; mersana; Novartis; Oncosec; pfizer; Puma Biotechnology; Seagen
Speakers' Bureau - Lilly
Research Funding - Acetylon Pharmaceuticals (Inst); Amgen (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Zeno Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pfizer
Other Relationship - Genentech; Immunomedics
 
Anthony W. Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Agenus (Inst); Aro Biotherapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Eleven Biotherapeutics (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pierre Fabre (Inst); Pyxis (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sunshine Guojian (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Vincerx Pharma (Inst); Zentalis (Inst); ZielBio (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Shushen Wang
No Relationships to Disclose
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Kolon Life Sciences; Lengo Therapeutics; Loxo; OnCusp Therapeutics; PACT Pharma; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
 
Robert Winkler
Employment - Ascentage Pharma Group
Stock and Other Ownership Interests - Ascentage Pharma Group
 
Mingyu Li
Employment - Ascentage Pharma Group
Stock and Other Ownership Interests - Ascentage Pharma Group
Research Funding - Ascentage Pharma Group
 
Xuemei Sun
Employment - Ascentage Pharma Group
Stock and Other Ownership Interests - Ascentage Pharma Group
 
Wentao Pan
Employment - Ascentage Pharma Group
Stock and Other Ownership Interests - Ascentage Pharma Group
 
ZHIYAN LIANG
Employment - Ascentage Pharma Group
Stock and Other Ownership Interests - Ascentage Pharma Group
Research Funding - Ascentage Pharma Group (Inst)
 
Ming Lu
Employment - Ascentage Pharma Group
Stock and Other Ownership Interests - Ascentage Pharma Group
Research Funding - Ascentage Pharma Group
 
Dajun Yang
Employment - Ascentage Pharma Group; Ascentage Pharma Group (I)
Leadership - Ascentage Pharma Group; Ascentage Pharma Group (I)
Stock and Other Ownership Interests - Ascentage Pharma Group; Ascentage Pharma Group (I)
Research Funding - Ascentage Pharma Group (Inst)
Patents, Royalties, Other Intellectual Property - Ascentage Pharma Group; Ascentage Pharma Group (I); Ascentage Pharma Group (Inst)
 
Yifan Zhai
Employment - Ascentage Pharma Group; Ascentage Pharma Group (I)
Leadership - Ascentage Pharma Group; Ascentage Pharma Group (I)
Stock and Other Ownership Interests - Ascentage Pharma Group; Ascentage Pharma Group (I)
Research Funding - Ascentage Pharma Group (Inst)
Patents, Royalties, Other Intellectual Property - Ascentage Pharma Group; Ascentage Pharma Group (I); Ascentage Pharma Group (Inst)